Logo image of CVM

CEL-SCI CORP (CVM) Stock Fundamental Analysis

NYSEARCA:CVM - NYSE Arca - US1508376076 - Common Stock - Currency: USD

8.7  +0.56 (+6.88%)

After market: 8.5 -0.2 (-2.3%)

Fundamental Rating

1

CVM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. Both the profitability and financial health of CVM have multiple concerns. CVM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CVM has reported negative net income.
In the past year CVM has reported a negative cash flow from operations.
CVM had negative earnings in each of the past 5 years.
CVM had a negative operating cash flow in each of the past 5 years.
CVM Yearly Net Income VS EBIT VS OCF VS FCFCVM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

CVM has a Return On Assets of -125.05%. This is amonst the worse of the industry: CVM underperforms 81.52% of its industry peers.
CVM's Return On Equity of -340.98% is on the low side compared to the rest of the industry. CVM is outperformed by 74.28% of its industry peers.
Industry RankSector Rank
ROA -125.05%
ROE -340.98%
ROIC N/A
ROA(3y)-76.3%
ROA(5y)-76.74%
ROE(3y)-142.28%
ROE(5y)-202.3%
ROIC(3y)N/A
ROIC(5y)N/A
CVM Yearly ROA, ROE, ROICCVM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M

1.3 Margins

CVM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVM Yearly Profit, Operating, Gross MarginsCVM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K

More info and screens

1

2. Health

2.1 Basic Checks

CVM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CVM has more shares outstanding
CVM has a better debt/assets ratio than last year.
CVM Yearly Shares OutstandingCVM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
CVM Yearly Total Debt VS Total AssetsCVM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -35.38, we must say that CVM is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -35.38, CVM is doing worse than 89.49% of the companies in the same industry.
CVM has a Debt/Equity ratio of 0.86. This is a neutral value indicating CVM is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.86, CVM is not doing good in the industry: 76.81% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -35.38
ROIC/WACCN/A
WACCN/A
CVM Yearly LT Debt VS Equity VS FCFCVM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.55 indicates that CVM may have some problems paying its short term obligations.
CVM has a worse Current ratio (0.55) than 91.85% of its industry peers.
CVM has a Quick Ratio of 0.55. This is a bad value and indicates that CVM is not financially healthy enough and could expect problems in meeting its short term obligations.
CVM has a worse Quick ratio (0.39) than 92.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.39
CVM Yearly Current Assets VS Current LiabilitesCVM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.66% over the past year.
EPS 1Y (TTM)32.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CVM will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.31% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.35%
EPS Next 2Y19.33%
EPS Next 3Y20.44%
EPS Next 5Y15.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CVM Yearly Revenue VS EstimatesCVM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2024 2026 2027 2028 2029 100M 200M 300M 400M
CVM Yearly EPS VS EstimatesCVM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CVM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CVM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVM Price Earnings VS Forward Price EarningsCVM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CVM Per share dataCVM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as CVM's earnings are expected to grow with 20.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.33%
EPS Next 3Y20.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CVM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CEL-SCI CORP

NYSEARCA:CVM (8/15/2025, 8:13:46 PM)

After market: 8.5 -0.2 (-2.3%)

8.7

+0.56 (+6.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12
Earnings (Next)01-12 2026-01-12/amc
Inst Owners5.07%
Inst Owner Change-92.9%
Ins Owners1.2%
Ins Owner Change8.72%
Market Cap59.33M
Analysts80
Price Target306 (3417.24%)
Short Float %22.84%
Short Ratio1.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3954.05%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.42
P/tB 7.55
EV/EBITDA N/A
EPS(TTM)-21.57
EYN/A
EPS(NY)-12.42
Fwd EYN/A
FCF(TTM)-2.64
FCFYN/A
OCF(TTM)-2.63
OCFYN/A
SpS0
BVpS1.17
TBVpS1.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.05%
ROE -340.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.3%
ROA(5y)-76.74%
ROE(3y)-142.28%
ROE(5y)-202.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.93%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.55
Quick Ratio 0.39
Altman-Z -35.38
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)143.31%
Cap/Depr(5y)116.55%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.06%
EPS Next Y6.35%
EPS Next 2Y19.33%
EPS Next 3Y20.44%
EPS Next 5Y15.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year717.49%
EBIT Next 3Y181.37%
EBIT Next 5YN/A
FCF growth 1Y12.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.08%
OCF growth 3YN/A
OCF growth 5YN/A